Hyperphosphatemia is a common complication in the later stages of chronic kidney disease (CKD). Sequelae can include hypocalcemia, disturbances in bone mineralization homeostasis, and an increased risk of adverse cardiovascular (CV) events. The management of hyperphosphatemia includes restricting the dietary intake of phosphate and use of phosphate binders to limit phosphate intake. Several different types of phosphate binders are available, but compliance, tolerability issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness of these agents. This report examines the management of hyperphosphatemia in dialysis and mid- to late-stage CKD patients. It provides insights into nephrologists’ attitudes and perceptions of older phosphate binders such as Fosrenol, Renvela, and Phoslyra, as well as the newer iron-based phosphate binders Velphoro and Auryxia.
- What are the most frequently prescribed phosphate binders among CKD patients undergoing dialysis and those not requiring dialysis?
- What are the most important drivers of and constraints to prescribing phosphate binders?
- How does current treatment differ by severity of hyperphosphatemia and CKD stage or by the need for dialysis?
- What are the most common reasons for the discontinuation of a phosphate binder?
Survey of 100 U.S. nephrologists.
KEY DRUGS COVERED
Auryxia, Velphoro, Fosrenol, Phoslyra, Renvela
KEY INSIGHTS PROVIDED
Factors influencing disease management and treatment decisions.
Drivers and constraints of treatment selection.
Physician-reported treatment practices and brand-level patient shares.
Rationale for changes in treatment approach.
Physician insight on persistency and compliance.
Physician-reported recent/anticipated changes in brand use or treatment approach.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
- Hyperphosphatemia - Current Treatment - Detailed, Expanded Analysis (US)
Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.)
Rameshwar Prajapati, Ph.D., M.S. (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications.
Rameshwar holds a bachelor’s degree in pharmacy from Dr. H.S. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, S.A.S Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.